Congress Materials – Florida Society of Clinical Oncology (FLASCO 2024)

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study

Shirish M. Gadgeel, Byoung Chul Cho, Shun Lu, Enriqueta Felip, Hidetoshi Hayashi, Alexander I. Spira, Benjamin Besse, Michael Thomas, Scott Owen, Yu Jung Kim, Se-Hoon Lee, Josiane Mourão Dias, Yun-Gyoo Lee, Yanqiu Zhao, Yong Fang, Nicolas Girard, Zhe Liu, Ping Sun, Sulene Cunha Sousa Oliveira, Hong Shen, Luis Paz-Ares, Shingo Matsumoto, Hiroshi Tanaka, Azura Rozila Ahmad, Timur Andabekov, Patrapim Sunpaweravong, Ozgur Ozyilkan, James Chih-Hsin Yang, Maya Gottfried, Osvaldo Hernandez, Martin Kimmich, Diego Cortinovis, Diego Lucas Kaen, Lizbett Vanessa García Montes, Sanjay Popat, Thomas Newsom-Davis, John Xie, Tao Sun, Elizabeth Fennema, Mahesh Daksh, Mariah Ennis, Seema Sethi, Joshua M. Bauml, Danny Nguyen

 

View poster